Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

AEterna cleared to commence phase III trial of AE-941 for treatment of kidney cancer

March 13, 2000

Malignant melanoma antisense compound enters pivotal trials

March 13, 2000

Patent covers charged tamoxifen derivatives for cancer therapy

March 13, 2000

Novel dinoflagellate-produced macrolide is cytotoxic to leukemia cells

March 10, 2000

Novel antitumor antibiotic identified from Streptomyces strain

March 10, 2000

Immune Response assesses brain tumor vaccine in phase I trial

March 10, 2000

The FDA approves Viadur for once-yearly palliative treatment of advanced prostate cancer

March 10, 2000

FDA grants fast track status to BNP-7787 for treating paclitaxel-induced neurotoxicity

March 10, 2000

MDM2 antisense inhibitor collaboration ended by Hybridon and Searle

March 10, 2000

Inducer of phenotypic reversion; isolation, structure and activity of new trichostatin

March 9, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...